Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.68

-2.4%

Dec 12 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: semi_infinite who wrote (14665)	12/14/2004 1:03:50 PM
From: Biomaven	Read Replies (2) of 52153

because ret specialists will make more money with it than Visudyne Never (alas) underestimate doctors' self-interest. When I was just getting started in biotech investing and was still naive I invested in a company that I think is still around - Matritech. They had a test that allowed follow-up for bladder cancer that avoided the need for visual inspection of the bladder wall. But guess what? Nobody ever got rich selling something to urologists that allowed them to avoid charging umpteen dollars for inserting something into an orifice for two minutes. Too bad if it's unpleasant for the patient - the insurance covers it with no questions asked. (I haven't looked for years, but I'm guessing Matritech is still struggling without much success to sell this test). Sometimes the doctor's self-interest isn't directly economic. It's degree of hassle. Thus if you are talking a drug that requires titration or monitoring, it's a much tougher sell. Write the script and forget is what's needed. Not talking all doctors of course - there are always a few noble souls out there that put their patients' interest first and also don't accept fancy lunches from pharma... Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next